Enzo Biochem ROE 2010-2022 | ENZ

Current and historical return on equity (ROE) values for Enzo Biochem (ENZ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Enzo Biochem ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-04-30 $-0.01B $0.06B -10.65%
2022-01-31 $0.00B $0.07B 0.00%
2021-10-31 $0.01B $0.07B 7.60%
2021-07-31 $0.01B $0.07B 10.98%
2021-04-30 $0.00B $0.07B 1.64%
2021-01-31 $-0.01B $0.06B -18.26%
2020-10-31 $-0.02B $0.06B -33.60%
2020-07-31 $-0.03B $0.06B -43.12%
2020-04-30 $-0.03B $0.06B -41.75%
2020-01-31 $0.00B $0.07B 1.23%
2019-10-31 $0.00B $0.08B 1.24%
2019-07-31 $0.00B $0.09B 3.75%
2019-04-30 $0.00B $0.09B 2.54%
2019-01-31 $-0.02B $0.07B -29.68%
2018-10-31 $-0.02B $0.08B -19.34%
2018-07-31 $-0.01B $0.08B -12.79%
2018-04-30 $-0.01B $0.09B -5.68%
2018-01-31 $-0.00B $0.09B -2.25%
2017-10-31 $-0.00B $0.09B -2.25%
2017-07-31 $-0.00B $0.09B -2.26%
2017-04-30 $0.03B $0.09B 38.31%
2017-01-31 $0.03B $0.09B 40.13%
2016-10-31 $0.04B $0.09B 56.14%
2016-07-31 $0.05B $0.09B 73.77%
2016-04-30 $0.02B $0.05B 34.52%
2016-01-31 $0.02B $0.05B 35.96%
2015-10-31 $0.01B $0.05B 12.58%
2015-07-31 $-0.00B $0.04B -8.11%
2015-04-30 $-0.01B $0.03B -39.44%
2015-01-31 $-0.01B $0.04B -30.14%
2014-10-31 $-0.01B $0.04B -30.77%
2014-07-31 $-0.01B $0.04B -28.57%
2014-04-30 $-0.01B $0.04B -29.20%
2014-01-31 $-0.02B $0.03B -47.76%
2013-10-31 $-0.02B $0.03B -50.70%
2013-07-31 $-0.02B $0.03B -49.03%
2013-04-30 $-0.04B $0.04B -101.18%
2013-01-31 $-0.04B $0.04B -75.83%
2012-10-31 $-0.04B $0.05B -60.80%
2012-07-31 $-0.04B $0.05B -52.96%
2012-04-30 $-0.02B $0.08B -18.35%
2012-01-31 $-0.01B $0.08B -16.33%
2011-10-31 $-0.02B $0.08B -17.98%
2011-07-31 $-0.01B $0.09B -14.05%
2011-04-30 $-0.02B $0.09B -15.87%
2011-01-31 $-0.02B $0.09B -18.56%
2010-10-31 $-0.02B $0.10B -21.95%
2010-07-31 $-0.02B $0.10B -21.90%
2010-04-30 $-0.02B $0.10B -20.00%
2010-01-31 $-0.02B $0.11B -18.34%
2009-10-31 $-0.02B $0.12B -15.97%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.104B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00